About Us
Our Product Pipeline

Developing scalable cells replacement therapies to treat incurable diseases for the world.

Our Market

We intend to be the benchmark for quality and affordability in cells therapies for our targeted conditions and expect to capture 1/6thof each of the following global markets:

Dry AMD~ USD 72 bn.
Retinitis Pigmentosa~ USD 10 bn.
Idiopathic Pulmonary Fibrosis~ USD 20 bn.

RPE cells – Phase

RPE cells – Immunocytochemistry
(PMEL17+ZO1+DAPI)

Our Lead Asset

EyeCyte-RPE replaces lost retinal pigment epithelium cells. It is designed to restore sight for patients in the early stages of Age-Related Macular Degeneration and arrest losses for those in the later stages.

The product is allogenic and administered by sub-retinal injection.
First in human application is scheduled for Q4 2022.

We are one of six players globally developing this solution.

Our Other Assets

EyeCyte-PRP replaces lost photoreceptor cells. It is proven in treating Retinitis Pigmentosa in animals. First in human application is scheduled for second half of 2023.

We are one of five players globally developing this solution.

PRP cells – Phase

PRP cells – Immunocytochemistry
(NRL2+RECOVERIN+DAPI)

AirCyte-AEC restore lung function for patients suffering from Idiopathic Pulmonary Fibrosis. The product is delivered to the alveolar surfaces by an intra-bronchial inhalation. Animal data is expected in June 2022.

We are the leading global player developing this solution.

Lung epithelial cells – Phase

Lung epithelial cells – Immunocytochemistry
(ARL13B+ZO1+DAPI)